DK1739166T3 - Fremstilling af fødevare- eller autoantigen-specifikke Tr1-celler fra en leukocyt- eller PBMC-population - Google Patents

Fremstilling af fødevare- eller autoantigen-specifikke Tr1-celler fra en leukocyt- eller PBMC-population

Info

Publication number
DK1739166T3
DK1739166T3 DK05291429.8T DK05291429T DK1739166T3 DK 1739166 T3 DK1739166 T3 DK 1739166T3 DK 05291429 T DK05291429 T DK 05291429T DK 1739166 T3 DK1739166 T3 DK 1739166T3
Authority
DK
Denmark
Prior art keywords
food
leukocyte
population
antigen
pbmc
Prior art date
Application number
DK05291429.8T
Other languages
English (en)
Inventor
Arnaud Foussat
Valerie Brun
Herve Groux
Francoise Cottrez
Original Assignee
Txcell S A
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Txcell S A, Inst Nat Sante Rech Med filed Critical Txcell S A
Application granted granted Critical
Publication of DK1739166T3 publication Critical patent/DK1739166T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4524—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/453—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95—Protein-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/53—CD2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/50—Coculture with; Conditioned medium produced by invertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK05291429.8T 2005-07-01 2005-07-01 Fremstilling af fødevare- eller autoantigen-specifikke Tr1-celler fra en leukocyt- eller PBMC-population DK1739166T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05291429A EP1739166B1 (en) 2005-07-01 2005-07-01 Obtention of food- or auto-antigen specific Tr1 cells from a leukocyte or PBMC population

Publications (1)

Publication Number Publication Date
DK1739166T3 true DK1739166T3 (da) 2011-10-10

Family

ID=36168439

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05291429.8T DK1739166T3 (da) 2005-07-01 2005-07-01 Fremstilling af fødevare- eller autoantigen-specifikke Tr1-celler fra en leukocyt- eller PBMC-population
DK06808973.9T DK1899459T3 (da) 2005-07-01 2006-07-03 Opnåelse af fødevare- eller autoantigenspecifikke tr1-celler fra en leukocyt- eller pbmc-population

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK06808973.9T DK1899459T3 (da) 2005-07-01 2006-07-03 Opnåelse af fødevare- eller autoantigenspecifikke tr1-celler fra en leukocyt- eller pbmc-population

Country Status (14)

Country Link
US (1) US7977093B2 (da)
EP (2) EP1739166B1 (da)
JP (2) JP5502322B2 (da)
AT (1) ATE513903T1 (da)
AU (1) AU2006271320B2 (da)
CA (1) CA2613778C (da)
CY (2) CY1112351T1 (da)
DK (2) DK1739166T3 (da)
ES (2) ES2368152T3 (da)
HU (1) HUE029143T2 (da)
PL (2) PL1739166T3 (da)
PT (2) PT1739166E (da)
SI (2) SI1739166T1 (da)
WO (1) WO2007010406A2 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852581B2 (en) * 2005-08-31 2014-10-07 Ith Immune Therapy Holdings Ab Treatment of inflammatory bowel disease
EP2050814A1 (en) * 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
US20100247577A1 (en) 2007-10-17 2010-09-30 Txcell Tr1 cells, mesenchymal stem cells and uses thereof
EP2062970A1 (en) * 2007-11-26 2009-05-27 Txcell Compositions for treating an intestinal inflammatory condition
EP2113560A1 (en) * 2008-04-28 2009-11-04 TXCell Compositions for treating an arthritic condition
PL2113254T3 (pl) 2008-04-28 2013-01-31 Txcell Kompozycje do leczenia autoimmunologicznego stanu zapalnego
EP2318020B1 (en) * 2008-06-30 2015-08-19 Universitätsklinikum Heidelberg Immunosuppressive blood cells and methods of producing same
GB0820397D0 (en) * 2008-11-07 2008-12-17 Cellerix Sa Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases
EP2221364A1 (en) * 2009-02-23 2010-08-25 TXCell Compositions for treating an allergic or asthmatic condition
WO2012131419A1 (en) 2011-03-25 2012-10-04 Txcell Method for using regulatory t cells in therapy
EP2982746A1 (en) 2014-08-07 2016-02-10 TXCell Regulatory T cells with therapeutic potential
KR101697473B1 (ko) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
EP3633029A4 (en) 2017-05-26 2021-06-09 Green Cross Lab Cell Corporation METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL
TWI832820B (zh) * 2017-07-21 2024-02-21 美商伯克利之光生命科技公司 抗原呈現合成表面、共價功能化表面、經活化之t細胞及其用途
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
KR102232321B1 (ko) * 2018-03-23 2021-03-26 주식회사 녹십자랩셀 자연살해세포의 제조방법
AU2019269601A1 (en) 2018-05-17 2020-11-26 Regents Of The University Of Minnesota Drug-resistant immune cells and methods of use thereof
MY199770A (en) 2018-11-14 2023-11-22 Green Cross Lab Cell Corp Method for culturing cord blood-derived natural killer cells using transformed t cells
PL238336B1 (pl) * 2019-08-22 2021-08-09 Gdanski Univ Medyczny Sposób otrzymywania in vitro antygenowo-specyficznych limfocytów T regulatorowych

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3926842B2 (ja) * 1995-03-08 2007-06-06 ザ・スクリプス・リサーチ・インステイチユート 抗原提示系およびｔ−細胞の活性化方法
US6670146B2 (en) * 2000-10-04 2003-12-30 Schering Corporation Regulatory T cells; methods
FR2824567B1 (fr) * 2001-05-11 2003-08-08 Inst Nat Sante Rech Med Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
FR2856700B1 (fr) 2003-06-24 2007-06-08 Txcell Procede d'identification de lymphocytes tr1 regulateurs par la presence et la surexpression de molecules specifiques et ses applications
EP1712615A1 (en) * 2005-04-15 2006-10-18 Txcell In vitro production of a cell population using feeder cells

Also Published As

Publication number Publication date
CY1112351T1 (el) 2015-12-09
PT1739166E (pt) 2011-09-22
EP1899459B1 (en) 2016-03-23
SI1899459T1 (sl) 2016-09-30
SI1739166T1 (sl) 2011-11-30
JP2008544760A (ja) 2008-12-11
CA2613778C (en) 2016-06-07
PL1739166T3 (pl) 2012-01-31
JP5502322B2 (ja) 2014-05-28
PT1899459T (pt) 2016-07-08
AU2006271320B2 (en) 2012-04-26
AU2006271320A1 (en) 2007-01-25
PL1899459T3 (pl) 2016-10-31
JP2013240334A (ja) 2013-12-05
US7977093B2 (en) 2011-07-12
ES2368152T3 (es) 2011-11-14
HUE029143T2 (hu) 2017-02-28
US20090075372A1 (en) 2009-03-19
WO2007010406A2 (en) 2007-01-25
CY1117772T1 (el) 2017-05-17
EP1739166A1 (en) 2007-01-03
CA2613778A1 (en) 2007-01-25
ATE513903T1 (de) 2011-07-15
ES2578259T3 (es) 2016-07-22
WO2007010406A3 (en) 2007-03-29
DK1899459T3 (da) 2016-07-18
EP1739166B1 (en) 2011-06-22
EP1899459A2 (en) 2008-03-19

Similar Documents

Publication Publication Date Title
DK1739166T3 (da) Fremstilling af fødevare- eller autoantigen-specifikke Tr1-celler fra en leukocyt- eller PBMC-population
Lexberg et al. Th memory for interleukin‐17 expression is stable in vivo
IL250313B (en) Expansion of renewable stem cell populations
DK0633929T3 (da) Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
ATE459652T1 (de) Verfahren zur herstellung von antikörpern
SG152273A1 (en) Pdx1 expressing endoderm
WO2007051038A3 (en) Pdx1-expressing dorsal and ventral foregut endoderm
EP1623017A4 (en) GENERATION AND ISOLATION OF ANTIGEN-SPECIFIC T CELLS
WO2003043486A3 (en) Matrix for the production of tissue engineered ligaments, tendons and other tissue
NO20033396L (no) Forbedret in vitro fremgangsmåte for dyrking av mammale celler for autologcelle implantasjon/transplantasjon fremgangsmåter
WO2004070013A3 (en) Use of islet 1 as a marker for isolating or generating stem cells
IL218447A0 (en) Co-culture lymphoid tissue equivalent (lte) for an artificial immune system (ais)
SG151246A1 (en) Tissue system with undifferentiated stem cells derived from corneal limbus
RU2008129788A (ru) Улучшенный способ увеличения числа опухоле-реактивных т-лимфоцитов в иммунотерапии онкологических больных
MX2021005480A (es) Metodos para aislar y expandir celulas.
EA200800996A1 (ru) Способ получения т-клеточной популяции
WO2006108882A8 (en) In vitro production of a cell population using feeder cells
DK1224264T3 (da) Anvendelse af allogene cellelinjer til at belaste antigenpræsenterende celler til at fremkomme med immunresponser
DK1784486T3 (da) Regenerering af nerver
WO2006026746A3 (en) Methods to separate and expand antigen-specific t cells
WO2001094551A3 (de) Gen-modifizierte t-zellen, verfahren zu ihrer herstellung und ihre verwendung
CY1107952T1 (el) Δενδριτικα κυτταρα ενεργοποιημενα εν τη παρουσια γλυκοκορτικοειδων ορμονων ειναι ικανα να καταστελλουν αντιγονο-ειδικες αποκρισεις κυτταρων
WO2005077048A3 (en) Immune modulation by regulating expression of the “minor” gene in immune dendritic cells
Moore et al. Dendritic cells and B cells cooperate in the generation of CD4+ CD25+ FOXP3+ allogeneic T cells
AR128988A1 (es) MÉTODO PARA EXPANDIR CÉLULAS T gd